logo
welcome
Reuters

Reuters

Roche shares drop on side effects result in early-stage obesity pill trial

Reuters
Summary
Nutrition label

81% Informative

Roche shares were down 4% at the open at 0700 GMT after the company presented details on the trial.

A brief summary of the study's success in July had boosted the Swiss drugmaker's share price.

Side effects from the drug known as CT-996 were mostly gastrointestinal ( GI ) like those associated with similar drugs.

VR Score

92

Informative language

99

Neutral language

64

Article tone

formal

Language

English

Language complexity

62

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links